Kleanthis G. Xanthopoulos, President and CEO at Regulus Therapeutics Inc. (RGLS), sold 5,700 shares at $19.50 ($112K) on 2015-01-30, disclosed to the SEC on 2015-02-03.
Scheduled sale ($112k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.50 | 3,300 | $64K | 57.6% |
| 2 | $19.77 | 2,400 | $47K | 42.4% |
| Total | $19.61 avg | 5,700 | $112K | 100% |
| Filing → |
| RGLS | SELL | 2015-03-05 | $1.8M | — | Filing → |
| RGLS | SELL | 2015-03-03 | $1K | — | Filing → |
| RGLS | SELL | 2015-01-30 | $2.6M | — | Filing → |